Previously treated with an HCV regimen containing an NS5A inhibitor Chronic Hepatitis C Genotype 1

Chronic Hepatitis C Genotype 1 Previously Treated with an NS5A Inhibitor Regimen

Chronic hepatitis C genotype 1 is a serious liver infection caused by the hepatitis C virus (HCV). It can lead to cirrhosis, liver cancer, and other life-threatening problems. The majority of people with hepatitis C genotype 1 (nearly 80%) will require treatment to help prevent these serious complications.

The standard of care for patients with chronic hepatitis C genotype 1 includes treatment with direct-acting antiviral (DAA) medications. A DAA regimen incorporating an NS5A inhibitor can be used to treat the virus. NS5A inhibitors are antiviral drugs that target a specific protein (called NS5A) that is essential for the virus to survive and replicate.

There is a variety of NS5A inhibitors available, including ledipasvir, ombitasvir, elbasvir, grazoprevir, pibrentasvir, sofosbuvir, and velpatasvir. These drugs are effective when used in combination with other DAAs to treat hepatitis C genotype 1. Studies have found that a DAA-based regimen containing an NS5A inhibitor can result in sustained virological response (SVR) rates of 95-100%. SVR is defined as the absence of detectable virus in the blood 24 weeks after the completion of treatment.

Patients with chronic hepatitis C genotype 1 who are being treated with an NS5A inhibitor-containing DAA regimen should be closely monitored for signs and symptoms of drug-related adverse events. Possible side effects of these drugs can include fatigue, headache, nausea, abdominal pain, and rash. If symptoms are severe or persist, it is important to seek medical advice from a healthcare provider.

  • Chronic hepatitis C genotype 1 is a serious liver infection caused by the hepatitis C virus (HCV).
  • The majority of people with hepatitis C genotype 1 (nearly 80%) will require treatment to help prevent serious complications.
  • A DAA regimen incorporating an NS5A inhibitor is a standard of care treatment for this condition.
  • NS5A inhibitors are antiviral drugs that target a specific protein (called NS5A) necessary for the virus to survive and replicate.
  • A DAA-based regimen containing an NS5A inhibitor can lead to an SVR rate of 95-100%.
  • Patients should be monitored for signs and symptoms of drug-related adverse events.
  • Intestinal Bacteria Flora
  • Scedosporium Infection
  • Endocrine Disorders
  • Spastic Pain of the Abdominal Wall
  • itchy skin
  • Ichthyosis Vulgaris
  • Hyperbilirubinemia
  • severe Pain
  • NYHA Functional Class II-III Pulmonary arterial hypertension
  • Infection caused by human papillomavirus type 31
  • Complement fixation test to C burnetii
  • How to Prepare Your Child for a Lab Test
  • Growth hormone suppression test
  • Eosinophilic esophagitis
  • Mental Health Screening
  • Allergy testing - skin
  • ALP - blood test
  • Calcium in Urine Test
  • Cerebrospinal fluid (CSF) collection
  • Visual acuity test